Aratana Therapeutics Inc. (NASDAQ:PETX) traded up 2% during mid-day trading on Tuesday . The company traded as high as $7.73 and last traded at $7.65, with a volume of 452,081 shares trading hands. The stock had previously closed at $7.50.

A number of equities research analysts have recently issued reports on the stock. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a report on Tuesday, April 26th. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, Lake Street Capital restated a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a report on Sunday, July 17th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Aratana Therapeutics presently has a consensus rating of “Buy” and an average target price of $11.66.

The stock’s 50 day moving average price is $6.61 and its 200-day moving average price is $5.50. The stock’s market cap is $269.34 million.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.10. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. During the same period in the prior year, the business earned ($0.26) EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities research analysts forecast that Aratana Therapeutics Inc. will post ($1.02) EPS for the current fiscal year.

In other Aratana Therapeutics news, CEO Peter Steven St sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $6.26, for a total value of $626,000.00. Following the completion of the sale, the chief executive officer now owns 717,793 shares in the company, valued at approximately $4,493,384.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the completion of the sale, the insider now owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Aratana Therapeutics stock. Jennison Associates increased its stake in shares of Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent filing with the SEC.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.